Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery.

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical differentiator for pharma companies, turning vast data streams into ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

“Content developers realise they need to be flexible in their approach. The modular content workflow is a little bit more rigid and can lend itself to creating large volumes of content in a more ...